Therefore, miR-155 regulation of SHIP-1 and SOCS1 expressions may be potential biomarkers and therapeutic targets for the treatment of pancreas-associated diseases (i.e., pancreatitis and pancreatic cancer). Here, SOCS1 is linked to pancreatic neoplasm.